Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

Studies Show ABT-263 and ABT-869 to be Promising in Targeting Cancer Cells'

Underlying Mechanisms

ABBOTT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Abbott scientists will highlight the latest clinical trial data of several investigative compounds in the company's oncology pipeline at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 in Chicago. The presentations include ABT-263, a Bcl-2 family protein antagonist, and ABT-869, an oral small molecule that provides simultaneously potent and specific inhibition of the VEGFR and PDGFR families. Both compounds were discovered by Abbott scientists and are being co-developed by Abbott and Genentech. The company's meeting abstracts are available online today at http://www.asco.org.

By targeting a key survival mechanism of cancer cells, Abbott scientists identified ABT-263 as a potent inhibitor of Bcl-2 family proteins. The Bcl-2 family proteins regulate apoptosis (programmed cell death), the natural process by which damaged or unwanted cells die and are cleared from the body. When this process is defective, damaged cells can continue to divide, leading to the formation and growth of tumors. Preclinical studies showed promising activity against chronic lymphocytic leukemia (CLL), lymphomas and small cell lung cancer -- Phase I/II trials are currently underway in these diseases.

Additionally, Abbott scientists are targeting another vital characteristic of cancer cells with ABT-869. In early studies, data have shown that ABT-869 inhibits a distinct set of kinases that are involved in angiogenesis, a process by which tumors gain access to new blood vessels. Inhibition of these kinases may suppress tumor growth by cutting off tumor blood supply. ABT-869 is currently being tested against several tumor types in Phase II clinical trials.

"Researchers from around the world have requ
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... conceived either less than one year or more than five ... increased risk for autism, a new study suggests. However, ... that the research can,t prove that birth spacing has any ... that parents understand that the odds for autism are still ... apart," said outside expert Dr. Andrew Adesman. He is chief ...
(Date:9/30/2014)... carbon emissions will reduce other harmful air pollution ... a new study released today. The research shows ... the final Clean Power Plan, the power plant ... hospitalizations, and hundreds of heart attacks in the ... Health Co-benefits of Carbon Standards for Existing Power ...
(Date:9/30/2014)... Health Day Reporter ... patients who are overweight or obese when diagnosed appear ... second weight-related cancer, new research suggests. , , The ... recurrence, only the potential for developing other cancers associated ... survivors who reported being overweight or obese prior to ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... 2014 Keystone Symposia will convene the first conference ... 2014-15 Global Health Series on "The Modes of ... immediately following the conclusion of the Grand Challenges ... part of the Keystone Symposia Global Health Series, supported ... also funded travel awards for 36 investigators from developing ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... new modus operandi at Britain’s farm ministry, with a view ... in the bud, as a preparation before the autumn season. ... gulls and waders, seen as potential H5N1 disseminators of infection ... surveillance and testing in the areas frequented by migratory birds. ...
... adults are estimated to use complementary and alternative therapies ... results of a// national survey published in the September ... issue on sleep. ,Approximately 10 to 34 ... as insomnia, according to background information in the article. ...
... Thiruvananthapuram said that there was no need to panic after ... were reported in the city.// ,Health authorities said that ... to pelt the state. The chikungunya scare so far was ... be confined to some pockets as mosquitoes are increasing due ...
... mosquito-caused illness is causing panic in the city.// ,As per ... city but four patients with its symptoms are being treated. Their ... have already started a survey in the city to identify chikungunya ... medical officer D.C. Jain. ,However, there is panic in ...
... fires have forced over 1,300 people to leave their ... to battle// the hundreds of forest fires on Friday. ... worst that they have ever encountered at this time ... with smoke vulnerability like children, the elderly, the infirm ...
... study directed by Mount Sinai School of Medicine ... regimens// might halt or even reverse symptoms of ... Attenuates Alzheimer’s Disease Type Brain Amyloidosis in Squirrel ... will be published in the November 2006 issue ...
Cached Medicine News:Health News:About 5 Percent of Adults with Insomnia Use Alternative Therapies 2Health News:Chikungunya Outbreak Feared in Jaipur 2Health News:Burning fires in Northern Ontario Cause Hundreds to leave their Homes 2Health News:Calorie Restriction May Prevent, Reduce Alzheimer’s Neuropatholog 2
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... is a microprocessor-controlled programmable power supply ... current and high current/low voltage applications ... is ideal for sample fractionation, IPG ... The low voltage/high current section is ...
... battery chargers are the ... GENIE blotters. They are ... specific voltages, giving much ... power supplies. 110 volt ...
... battery chargers are the ... GENIE blotters. They are ... specific voltages, giving much ... power supplies. 110 volt ...
Inquire...
Medicine Products: